Ireland
--:--IST
Clinical Trials in the EU / 2025-520688-42-00
Authorised, recruitment ended Phase II

A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)

2025-520688-42-00 · tracked via the Priya Life Science EU tracker
Sponsor
Phenonet Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
21/10/2025
Enrollment target
128
Sites
Germany, Czechia, Poland, Spain

Condition studied

Amyotrophic Lateral Sclerosis (ALS)

Investigational medicinal product(s)

PHENOGENE-1aPlacebo capsuleoral inhalation via DPI

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Absolute change in ALSFRS-R total score from baseline to Week 24.

Endpoint detail

Mean rank for CAFS across all by treatment group at Week 24., Time to event requiring full-time or nearly full-time respiratory support., Mean change in %FVC from baseline to Week 24., Mean change in PIFR from baseline to Week 24.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-520688-42-00 on CTIS ↗ ← All trials in the EU